Joseph S. Manni
Known title: Chief Revenue OfficerCIK: 0002060118
Associated companies
Transaction History
| CBLL | ▼ Sell | Open Market | 1,361 | $33K | 8/21/2026 | View on chart |
| CBLL | ▼ Sell | Open Market | 1,378 | $25K | 5/21/2026 | View on chart |
| CBLL | ▲ Buy | Grant | 30,736 | $0 | 4/1/2026 | View on chart |
| CBLL | ▼ Sell | Open Market | 768 | $15K | 2/23/2026 | View on chart |
| CBLL | ▼ Sell | Tax Withholding | 660 | $9K | 11/20/2025 | View on chart |
| CBLL | ▼ Sell | Tax Withholding | 660 | $8K | 8/25/2025 | View on chart |
| CBLL | ▲ Buy | Grant | 28,421 | $0 | 4/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CeriBell Gets FDA Clearance for New EEG Analysis Tools
CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.
CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.